Contributed by
Every sales team has a deal like this. The prospect loved the demo, the contact replies within the hour, the proposal went out weeks ago. Quarter after quarter it sits at 'commit' and never signs. When someone finally asks who approves the spend, nobody knows.
That deal was never qualified. It was hoped for. MEDDIC exists to close the gap between hope and evidence, and for mid-to-large B2B deals it remains the most dependable qualification discipline there is.
Key insights
- It came from a fast-growing sales team. MEDDIC was created in 1996 by Dick Dunkel at PTC (Parametric Technology Corporation), working under sales leader John McMahon with Jack Napoli.
- The results made it famous. The discipline behind MEDDIC is credited with helping PTC's sales organisation grow from $0 to $1 billion in ten years.
- Forecast confidence is still low. A Gartner survey found only 45% of sales leaders and sellers have high confidence in their organisation's forecasting accuracy.
- Leaders trust their own read more than their reps'. In Gong's 2022 forecasting research, just 24% of sales leaders trusted their reps' forecast commitments, compared with 58% who trusted their own.
The six letters
MEDDIC stands for six things a rep should know before calling a deal qualified.
Metrics. What measurable result does the customer expect? Lower costs, faster turnaround, fewer errors. If the buyer can't put a number on the outcome, the business case will be weak when it reaches finance.
Economic buyer. Who has the final say on the money? This is rarely the person attending the demos. A deal without access to the economic buyer is a deal at risk.
Decision criteria. What will the customer use to compare options? Price, integration, support, local presence. Knowing the criteria early lets the team shape them, rather than react to them.
Decision process. How will the decision actually be made? Who gets involved, in what order, and how long each step takes.
Identify pain. What problem is hurting enough to justify change? Without real pain, deals drift, because doing nothing is always the cheapest option.
Champion. Who inside the customer wants this to happen and has the influence to push it? A champion sells for you in the meetings you aren't invited to.
Why it works
MEDDIC's strength is that it replaces opinion with evidence. 'The client is keen' becomes 'we've met the CFO, we know the decision will be made by a committee of four in March, and the operations head is pushing for us.' That is a statement a sales manager can check, challenge and forecast against.
It also exposes weak deals early. A rep who can't name the economic buyer after three meetings learns something important, and it's better to learn it in week three than at quarter end.
Where it can go wrong
The most common mistake is treating MEDDIC as a form to fill in after the call, rather than a guide to what to learn on the call. Reps tick boxes with guesses, and the pipeline looks qualified when it isn't.
The other risk is applying it to every deal. For a small, quick sale, six letters of qualification is too much. MEDDIC earns its keep on larger deals with longer cycles and several people involved. For very large or highly competitive deals, many teams move to MEDDPICC (https://interloop.in/blogs/meddpicc-sales-framework), which adds two more letters.
Putting MEDDIC into the pipeline
MEDDIC is most useful when it's visible in the place deals are managed. Each letter becomes a field on the deal record, and the pipeline stages are tied to how much of MEDDIC has been confirmed. A deal can't reach 'proposal' without a named economic buyer, for instance, or 'commit' without a confirmed decision process.
Zoho CRM is a good example of how this can be set up. Teams add MEDDIC fields to the Deals module, use Blueprint to make specific answers mandatory before a stage change, and build a simple report that shows which deals in the Zoho CRM sales pipeline are missing which letters. Done during a Zoho CRM implementation, it makes MEDDIC part of how the system works rather than an extra step.
If you're comparing qualification approaches more broadly, our overview of B2B sales frameworks (https://interloop.in/blogs/b2b-sales-frameworks) sets MEDDIC alongside the others.
Our view
MEDDIC is a management tool first and a selling tool second. Its real value shows up in the deal review, when a manager asks 'who is the economic buyer?' and gets a name, not an adjective.
People. Reps resist MEDDIC when it feels like policing. They embrace it when managers use it to help them win, by spotting the missing letter before the customer does.
Process. Tie each pipeline stage to specific letters. A deal without a confirmed decision process is not in 'commit', whatever the rep's instinct says.
Intelligence. Over two or three quarters, lost deals reveal which letter your team skips most often. Fix that one first.
The most common misreading of MEDDIC is treating the champion as anyone friendly. A champion has influence and a personal stake in your success; a friendly contact without either is a coach at best. We would also not use MEDDIC for transactional sales that close in a few weeks. It is built for deals where getting qualification wrong is expensive.
Signs it's working
Forecast calls get shorter and calmer. Fewer 'commit' deals slip to the next quarter. Win rates on qualified deals rise, even if the total number of deals in the pipeline falls. And when a deal is lost, the team can usually point to the letter that was never confirmed.
Qualification does not make every deal winnable. It makes the unwinnable ones obvious, early, while it still matters.
